The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia
Abstract
Zaleplon (N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethyl acetamide) is a non-benzodiazepine recently introduced for clinical use. This agent is indicated for the short-term treatment of insomnia. Preclinical studies have shown that the benzodiazepines triazolam and Ro17-1812 can substitute for zaleplon in animals trained to distinguish zaleplon from saline. The benzodiazepine antagonist flumazenil can antagonise the discriminative stimulus effect of zaleplon. These findings suggest that zaleplon is recognised by animals as a benzodiazepine agent. Zaleplon is active after ip. and oral administration in a variety of motor performance tests, including locomotor activity, rotarod and the loaded grid. Zaleplon has been shown to be active in a number of different anticonvulsant models, including the pentylenetetrazole, isoniazid and electroshock models. The compound is also reported to be active against convulsions induced by bicuculline, picrotoxin and strychnine. Studies in anxiolytic models suggest that zaleplon may have weak anxiolytic activity. From preclinical studies, it appears zaleplon possesses a reduced risk of tolerance compared to triazolam, is less likely to potentiate the effects of ethanol and is unlikely to produce amnestic effects. In man, zaleplon is rapidly absorbed and undergoes extensive presystemic metabolism. The compound has a plasma half-life of approximately one hour and is metabolised primarily via the aldehyde oxidase system to form 5-oxo-zaleplon. This metabolite, along with other minor metabolites formed in vivo, do not appear to contribute to the activity of zaleplon. Metabolites of zaleplon are excreted primarily via the urine. Phase I studies suggest that single daytime doses of zaleplon up to 15 mg are well-tolerated. Short-term impairment of performance occurs when zaleplon is administered during the day at doses epsilon 20 mg. However, given the short half-life of the compound, significant impairment of daytime performance is unlikely if zaleplon is administered at bedtime or shortly after retiring for the evening. Results from Phase II/III studies suggest that zaleplon (5 - 20 mg) produces a dose-dependent reduction in sleep latency in patients suffering from primary insomnia. The clinical efficacy of zaleplon persists for at least four weeks at doses of 10 mg and 20 mg. Studies in patients with a history of drug abuse suggest that the abuse potential of zaleplon (at doses above the therapeutic dose range) is similar to that seen with the benzodiazepine triazolam.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
Rebound Insomnia and Rebound Anxiety: A Review
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000137794 · Cited by 198
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
Perrault, G., Morel, E., Sanger, D. J., & Zivkovic, B. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10339-x · Cited by 110
Allen, D., Curran, H. V., & Lader, M. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265843 · Cited by 51
Garratt, J. C., Paul Gent, J., Feely, M., & Haigh, J. R. M. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90351-2 · Cited by 34
Cited by
Allain, H., Bentu??-Ferrer, D., Polard, E., Akwa, Y., & Patat, A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522090-00004 · Cited by 214
“[48] were identified in the literature.”
IS THERE A RATIONALE FOR PRESCRIPTION OF BENZODIAZEPINES IN THE ELDERLY? REVIEW OF THE LITERATURE
Petrovic, M., Mariman, A., Warie, H., Afschrift, M., & Pevernagie, D. (2003) · Acta Clinica Belgica · doi:10.1179/acb.2003.58.1.004 · Cited by 76
“zopiclone and zaleplon interact with BZD receptors (2, 3).”
Background
Metadata
- Authors
- Heydorn, W. E.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2000-04
- Volume
- 9
- Issue
- 4
- Pages
- 841-858
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2123542917
- Cited by
- 195
- References
- 6
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia. https://app.cochat.ai/papers/10.1517/13543784.9.4.841
- The paper
- Heydorn, W. E. (2000). Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.9.4.841
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.